MiniMed (MMED) expands board and sets October 2026 virtual annual meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
MiniMed Group, Inc. announced governance updates and its next shareholder meeting plans. The Board of Directors increased its size from nine to 11 members and appointed David Endicott and Linnea Burman as new directors, effective June 29, 2026.
Endicott will serve as a Class I director with a term expiring at the 2026 annual meeting and join the Compensation and Talent Committee. He is currently Chief Executive Officer and a director of Alcon, Inc., and has prior senior roles at several healthcare companies. The Board determined he is independent under Nasdaq, SEC and company guidelines.
Burman, a senior executive at Medtronic plc, will serve as a Class II director with a term expiring at the 2027 annual meeting. While Medtronic remains an affiliate of MiniMed, she will not receive Board compensation. MiniMed also set its 2026 annual meeting of stockholders for October 9, 2026, with an August 11, 2026 record date and mid‑July deadlines for shareholder proposals and nominations.
Positive
- None.
Negative
- None.
8-K Event Classification
4 items: 5.02, 5.08, 8.01, 9.01
4 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.08
Shareholder Director Nominations
Governance
Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size: 11 directors
Effective date of new directors: June 29, 2026
2026 annual meeting date: October 9, 2026
+3 more
6 metrics
Board size
11 directors
Increased from nine members on June 25, 2026
Effective date of new directors
June 29, 2026
Start of service for Endicott and Burman
2026 annual meeting date
October 9, 2026
Virtual meeting at 9:00 a.m. Pacific Time
Record date
August 11, 2026
Determines stockholders entitled to vote
Rule 14a-8 proposal deadline
July 26, 2026
Cutoff for inclusion in 2026 proxy materials
Bylaw notice deadline
July 17, 2026
Deadline for director nominations or other business
Key Terms
emerging growth company, Item 404(a) of Regulation S-K, Rule 14a-8, record date, +1 more
5 terms
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 404(a) of Regulation S-K regulatory
"does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K"
Rule 14a-8 regulatory
"To be included in the proxy materials for the 2026 Annual Meeting, stockholder proposals submitted in compliance with Rule 14a-8 must be received"
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
record date financial
"The Board has fixed the close of business on Tuesday, August 11, 2026 as the record date for determining the stockholders entitled"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
proxy materials financial
"no later than July 26, 2026, which MiniMed has determined to be a reasonable time before it expects to begin printing and distributing its proxy materials"
Proxy materials are the packet of documents sent to shareholders that explain items to be voted on at a company meeting and include the actual ballot or instructions for casting a vote. Think of them as a voting packet that lays out who’s running the company, major proposals (like pay, mergers, or board changes), and arguments for and against each item. Investors care because those votes shape corporate direction, affect risk and future profits, and can influence share value.
FAQ
What board changes did MiniMed (MMED) disclose in this 8-K?
MiniMed expanded its Board from nine to 11 directors and appointed David Endicott and Linnea Burman effective June 29, 2026. Endicott joins as an independent Class I director and Burman as a Class II director.
When is MiniMed’s 2026 annual meeting of stockholders scheduled?
MiniMed set its 2026 annual meeting for October 9, 2026 at 9:00 a.m. Pacific Time, to be held virtually. Stockholders of record as of August 11, 2026 are entitled to notice and voting rights.
How can stockholders nominate directors for MiniMed’s 2026 annual meeting?
Eligible stockholders must provide advance notice under MiniMed’s Bylaws by July 17, 2026 to nominate directors or introduce business at the 2026 meeting. Notices must comply with Delaware law, SEC rules and the company’s bylaws.
Will Linnea Burman be paid for serving on MiniMed’s Board?
For so long as Medtronic is an affiliate of MiniMed, Burman, as a Medtronic employee, will receive no compensation for Board service. After that, her compensation will match MiniMed’s other non‑employee directors.
Is new director David Endicott considered independent at MiniMed (MMED)?
Yes. The Board determined that David Endicott is independent under Nasdaq rules, SEC standards and MiniMed’s corporate governance guidelines, and he has no material interests requiring disclosure under Item 404(a) of Regulation S‑K.